Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Supplementary Figure 3 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Home
Publications
Supplementary Figure 3 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Supplementary Figure 3 from First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Authors:
WZ
Wenjie Zhang
Wenjie Zhang
JW
Jing Wang
Jing Wang
WS
Wei Shi
Wei Shi
HQ
Hu Qiu
Hu Qiu
SK
Shaobo Ke
Shaobo Ke
YT
Yuanyuan Tian
Yuanyuan Tian
YG
Yi Gong
Yi Gong
CZ
Caiyutian Zhang
Caiyutian Zhang
JC
Jiamei Chen
Jiamei Chen
YW
Yong Wu
Yong Wu
WZ
Wensi Zhao
Wensi Zhao
YC
Yongshun Chen
Yongshun Chen
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Open Access
Publisher website
Google Scholar
17 June 2026
other
Published by
American Association for Cancer Research (AACR)
DOI:
10.1158/1535-7163.32708791
Abstract
Supplementary Figure 3. Baseline systemic immunity markers (NLR, ALC, PLR, and LMR), blood biomarkers(CEA, CA199, CA72–4 and CA50) and lipid levels(TCH,TG, LDL-Ch and HDL-Ch) were not statistically associated with therapeutic response and PFS. NS = No significance; ALC = absolute lymphocyte count; NLC = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; LMR = lymphocyte-to-monocyte ratio; TCH = total cholesterol; TG = triglycerides; LDL-Ch = low density lipoprotein-cholesterol; HDL-Ch = high density lipoprotein-cholesterol; PR = partial response; SD = stable disease; PD = progressive disease; PFS = progression-free survival.
Keywords
CHEMOTHERAPY
COMBINATION CHEMOTHERAPY
CLINICAL TRIAL RESULTS
GASTROINTESTINAL CANCERS
STOMACH CANCER
IMMUNOTHERAPY
Related articles
Scroll to top